Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma

Blood

Volumn 100, Issue 13, 2002, Pages 4629-4639

  Borson, Nancy D ^a   Lacy, Martha Q ^a   Wettstein, Peter J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ISOPROTEIN; MELPHALAN; MESSENGER RNA; PREDNISONE; PROTEIN; PROTEIN BLIMP 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HYPOTHESIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY;

EID: 0037114695     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.13.4629     Document Type: Article

References (55)

1. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
2. Reichardt V, Okada C, Benike C, et al. Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation [abstract]. Blood. 1996;10(suppl):481a.
3. Kwal LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016-1020.
4. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors [see comments]. N Engl J Med. 1992;327:1209-1215.
5. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: Depletion of CD4 T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol. 1996;26:2671-2679.
6. Bogen B, Munthe L, Sollien A, et al. Naive CD4 T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol. 1995;25:3079-3086.
7. Yi Q, Osterborg A, Bergenbrant S, et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammapothies. Blood. 1995;86:3043-3049.
8. Osterborg A, Yi Q, Bergenbrandt S. Idiotype-specific T cells in multiple myeloma stage I: An evaluation by four different functional tests. Br J Haematol. 1995;89:110-116.
9. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655.
10. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood. 1999;93:2411-2419.
11. McClelland M, Welsh J. RNA fingerprinting by arbitrarily primed PCR. PCR Methods Appl. 1994;4:S66-S81.
12. Hagman J, Wheat W, Fitzsimmons D, Hodsdon W, Negri J, Dizon F. Pax-5/BSAP: Regulator of specific gene expression and differentiation in B lymphocytes. Curr Top Microbiol Immunol. 2000;245:169-194.
13. Zwollo P, Arrieta H, Ede K, Molinder K. Desiderio S, Pollock R. The Pax-5 gene is alternatively spliced during B-cell development. J Biol Chem. 1997;272:10160-10168.
14. Usui T, Wakatsuki Y, Matsunaga Y, Kaneko S, Kosek H, Kita T. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol. 1997;158:3197-3204.
15. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br J Haematol. 2002;116:429-435.
16. Lin K, Angelin-Duclos C, Kuo T, Calame K. Blimp-1 dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol. 2002;22:4771-4780.
17. Soro PG, Morales AP, Martinez MJA, et al. Differential involvement of the transcription factor Blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells. J Immunol. 1999;163:611-617.
18. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol. 2000;165:5462-5454.
19. McClelland M, Ralph D, Cheng R, Welsh J. Interactions among regulators of RNA abundance characterized using RNA fingerprinting by arbitrarily primed PCR. Nucleic Acids Res. 1994;22:4419-4431.
20. Bauer D, Muller H, Reich J, et al. Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR). Nucleic Acids Res. 1993;21:4272-4280.
21. Borson ND, Strausbauch MA, Wettstein PJ, Oda RP, Johnston SL, Landers JP. Direct quantitation of RNA transcripts by competitive single-tube RTPCR and capillary electrophoresis. Biotechniques. 1998;25:130-137.
22. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403-410.
23. Dorfler P, Busslinger M. C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. EMBO J. 1996;15:1971-1982.
24. Kaneko H, Ariyasu T, Inoue R, et al. Expression of Pax5 gene in human haematopoietic cells and tissues: Comparison with immunodeficient donors. Clin Exp Immunol. 1998;111:339-344.
25. Barberis A, Widenhorn K, Vitelli L, Busslinger M. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev. 1990;4:849-859.
26. Adams B, Dorfler P, Aguzzi A, et al. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev. 1992;6:1589-1607.
27. Nomura N, Miyajima N, Sazuka T, et al. Prediction of the coding sequences of unidentified human genes. DNA Res. 1994;1:47-56.
28. Bouchard M, Pfeffer P, Busslinger M. Functional equivalence of the transcription factors Pax2 and Pax5 in mouse development. Development. 2000;127:3703-3713
29. Kozmik Z, Holland ND, Kalousova A, et al, Characterization of an amphioxus paired box gene, AmphiPax2/5/8: Developmental expression patterns in optic support cells, nephridium, thyroid-like structures and pharyngeal gill sits, but not in the midbrain-hindbrain boundary region. Development. 1999;126:1295-1304.
30. Knodel M, Kuss AW, Lindemann D, Berberich I, Schimpl A. Reversal of Blimp-1-mediated apoptosis by A1, a member of the Bcl-2 family. Eur J Immunol. 1999;29:2988-2998.
31. Zwollo P, Arrieta H, Ede K, Molinder K, Desiderio S, Pollock R. The Pax-5 gene is alternatively spliced during B-cell development. J Biol Chem. 1997;272:10160-10168.
32. Wallin JJ, Gackstetter ER, Koshland ME. Dependence of BSAP repressor and activator functions on BSAP concentration. Science. 1998;279:1961-1964.
33. Gisler R, Akerblad P, Sigvardsson M. A human early B-cell factor-like protein participates in the regulation of the human CD19 promoter. Mol Immunol. 1999;36:1067-1077.
34. Liao F, Birshtein BK, Busslinger M, Rothman P. The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line epsilon transcription. J Immunol. 1994;152:2904-2911.
35. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (PAX-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 2000;17:2319-2333.
36. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 1995;14:5638-5645.
37. Hamada T, Yonetani N, Ueda C, et al. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9:14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Br J Haematol. 1998;102:691-700.
38. Stuart ET, Kioussi C, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res. 1995;1:207-214.
39. Kozmik A, Sure U, Ruedi D, Busslinger M. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A. 1995;92:5709-5713.
40. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
41. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
42. Bell MV, Cowper AE, Lefranc MP, Bell JI, Screaton GR. Influence of intron length on alternative splicing of CD44. Mol Cell Biol. 1998;18:5930-5941.
43. Chabot B. Directing alternative splicing: Cast and scenarios. Trends Genet. 1996;12:472-478.
44. Lopez AJ. Alternative splicing of PRE-mRNA: Developmental consequences and mechanisms of regulation. Annu Rev Genet. 1998;32:279-305.
45. McNaughton JC, Hughes G, Jones WA, Stockwell PA, Klamut HJ, Petersen GB. The evolution of an intron: Analysis of a long, deletion-prone intron in the human dystrophin gene. Genomics. 1997;40:294-304.
46. Li L, Ohman T, Deeb S, Fukuchi K. Analysis of mouse intron 7 DNA sequence of the APP gene: Comparison with the human homologue. DNA Seq. 2000;10:219-228.
47. Rohlfs EM, Puget N, Graham ML, et al. An alumediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer. 2000;28:300-307.
48. Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J Hum Genet. 1999;65:1330-1341.
49. Kaufmann D, Leistner W, Kruse P, et al. Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2. Cancer Res. 2002;62:1503-1509.
50. Eberhard D, Busslinger M. The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. Cancer Res. 1999;59:1716-1725.
51. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1991;88:7605-7609.
52. Juge-Morineau N, Harousseau JL, Amiot M, Bataille R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk Lymphoma. 1997;24:229-237.
53. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997;276:596-599.
54. Messika EJ, Lu PS, Sung YJ, et al. Differential effect of B lymphocyte-induced maturation protein (Blimp-1) expression on cell fate during B cell development. J Exp Med. 1998;188:515-525.
55. Knodel M, Kuss AW, Berberich I, Schimpl A. Blimp-1 overexpression abrogates IL-4- and CD40-mediated suppression of terminal B cell differentiation but arrests isotype switching. Eur J Immunol. 2001;31:1972-1980.